@josh__hardman : It's a tricky time for Lykos to raise money from more conventional biotech investors. Not only did it receive a rejection from the FDA last summer, but it also received two major rejections from the US Patent and Trademark Office, which have gone largely unreported. • TwiCopy

josh hardman

@josh__hardman

+ Follow

Covering all aspects of psychedelics at @Psyched_Alpha. Full of microplastics.

ID: 1344083599889469440

linkhttps://joshdidit.com/ calendar_today30-12-2020 00:51:26

2,2K Tweet

3,3K Takipçi

345 Takip Edilen

josh hardman

@josh__hardman

8 months ago

It's a tricky time for Lykos to raise money from more conventional biotech investors. Not only did it receive a rejection from the FDA last summer, but it also received two major rejections from the US Patent and Trademark Office, which have gone largely unreported.

thumb_up_off_alt18

chat_bubble_outline3

repeat1

shareShare